[1] 陈万青,郑荣寿,张思维,等.2012年中国恶性肿瘤发病和死亡分析[J].中国肿瘤,2016,25(1):1~8.
[2] 中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2015版)[J].中国癌症杂志,2015,25(9):692~754.
[3] EBCTCG. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials [J]. Lancet, 2005, 365: 1687~1717.
[4] 单明,康文莉,张国强.CYP2D6基因多态性对乳腺癌治疗中他莫昔芬药物疗效的影响[J].中华乳腺病杂志,2017,11(4):238~242.
[5] Henning EE, Piatkowska M, Karczmarski J, et al. Limited predictive value of achieving beneficial plasma (Z) -endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer [J]. BMC Cancer,2015,15:570.
[6] Herta DL, Deal A, Ibrahim JG, et al. Tamoxifen dose escalation in patients with diminished CYP2D6 activity normalizes endoxifen concentration without increasing toxicity [J]. Oncologist, 2016, 21(7): 795~803.
[7] Ramony Cajal, Altes A, Pare L, et al. Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment [J]. Breast Cancer Res Treat, 2010, 119(1): 33~38.
[8] Gradishar WJ, Anderson BO, Balassanian R, et al. Invasive Breast Cancer Version 1 2016, NCCN Clinical Practice Guidelines in Oncology [J].Natl Compr Canc Netw, 2016, 14(3): 324~354. |
2018, Vol. 24 
